Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Oct 20 - Oct 25
Phase 3 clinical trial data showed average weight loss of 28.7% of body weight (approximately 71.2 pounds) at the 12 mg dose over 68 weeks
There will be an evidentiary hearing on May 14, 2025
Differentially expressed proteins and associated histological and disease progression changes in cotyledon tissue of a resistant and susceptible genotype of Brassica napus infected with Sclerotinia sclerotiorum
TOLERABILITY AND ADVERSE EVENTS The most common adverse events associated with GLP-1 receptor agonist use in general are gastrointestinal in nature, with mild-to-moderate diarrhea, nausea, and vomiting being the most commonly reported events
In order to achieve the purpose, the technical scheme of the invention is as follows: the high-stability reduced glutathione for injection is characterized in that: when the amount of the reduced glutathione is 0.6g, the formula components are as follows: reduced glutathione 0.6g Adjusting the pH of the solution to 6.0-7.0 with 10% sodium hydroxide solution Adding water for injection to 2g When the amount of the reduced glutathione for injection is 1.0g, the formula components are as follows: reduced glutathione 1.0g Adjusting the pH of the solution to 6.0-7.0 with 10% sodium hydroxide solution Adding water for injection to 3.3g When the reduced glutathione for injection is 1.5g, the formula components are as follows: reduced glutathione 1.5g Adjusting the pH of the solution to 6.0-7.0 with 10% sodium hydroxide solution Adding water for injection to 5.0g Wherein, in the liquid preparation process, nitrogen is continuously filled in the liquid preparation and filling processes to keep the oxygen content in the solution below 1.5 ppm
US$ 28.75
US$ 24.23
US$ 25.16
US$ 23.89
US$ 28.25
US$ 29.00
US$ 28.16
US$ 24.01
US$ 24.63
